temozolomide has been researched along with Breast Neoplasms in 51 studies
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis." | 9.69 | Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. ( Anders, CK; Arisa, O; Armstrong, TS; Brastianos, P; Burton, E; Carter, S; Connolly, RM; Figg, WD; Gilbert, MR; Houston, N; Jenkins, S; Khan, I; Lipkowitz, S; Mendoza, TR; Mozarsky, B; Nousome, D; Peer, CJ; Shah, R; Smart, DD; Smith, KL; Steeg, PS; Steinberg, SM; Tweed, C; Vera, E; Wu, X; Zhang, W; Zimmer, AS, 2023) |
| "Veliparib and temozolomide demonstrated clinical activity in platinum-naïve BRCA-associated metastatic breast cancer with manageable toxicity at doses of veliparib well below the single-agent active dose." | 9.41 | Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. ( Chabner, BA; Ellisen, LW; Garber, JE; Gelman, RS; Goss, PE; Habin, K; Isakoff, SJ; Keenan, TE; Overmoyer, B; Tung, NM; Winer, EP; Xu, J; Yeap, BY, 2021) |
| " This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer." | 9.27 | Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. ( Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML, 2018) |
| "Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clinical trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer." | 9.24 | A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. ( Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Giranda, VL; Han, HS; Isakoff, SJ; Johnson, EF; Kaufman, B; Maag, D; Puhalla, S; Qin, Q; Robson, M; Shepherd, SP; Telli, ML, 2017) |
| "To improve the therapeutic index of whole-brain radiation therapy (WBRT) in the treatment of brain metastases (BM) from breast cancer, we investigated the efficacy and safety of WBRT combined with temozolomide (TMZ) in this population." | 9.20 | Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. ( Bourgier, C; Cao, KI; Gerber, S; Gobillion, A; Kirova, YM; Le Scodan, R; Lebas, N; Levy, C; Pierga, JY; Savignoni, A, 2015) |
| "This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma." | 9.14 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010) |
| "Temozolomide is an oral alkylating agent that crosses the blood-brain barrier, and has preclinical activity in breast cancer." | 9.12 | Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). ( Bordeleau, L; Charpentier, D; Crump, M; Eisenhauer, E; Matthews, S; Trudeau, ME; Yelle, L, 2006) |
| "Temozolomide profoundly prevented the outgrowth of experimental brain metastases of breast cancer in an MGMT-dependent manner." | 7.80 | Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. ( Biernat, W; Duchnowska, R; Gril, B; Hewitt, SM; Hua, E; Jassem, J; Liewehr, DJ; Palmieri, D; Qian, Y; Sosińska-Mielcarek, K; Stark, AM; Steeg, PS; Steinberg, SM; Woditschka, S, 2014) |
| "A case is reported in which temozolomide, a promising new DNA alkylating agent, was successfully used to treat radiation refractory metastatic brain tumors arising from primary breast cancer." | 7.71 | Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report. ( Isaacson, BJ; Islam, R; Ratanawong, C; Tipping, SJ; Zickerman, PM, 2002) |
| "Primary end point is freedom from new brain metastases at 1 year." | 6.94 | Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. ( Armstrong, TS; Biassou, N; Brastianos, PK; Burton, E; Carter, S; Gilbert, MR; Gril, B; Houston, N; Lipkowitz, S; Lyden, D; Smart, DD; Steeg, PS; Steinberg, SM; Zimmer, AS, 2020) |
| "The standard treatment for brain metastases is radiotherapy." | 6.55 | Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. ( Luo, Y; Tang, J; Tian, J; Xiang, J, 2017) |
| "Human breast cancer is among one major health concerns with high prevalence and mortality among women worldwide." | 5.91 | Novel Synergistic Combination of Pamidronate and Temozolomide for Breast Cancer Therapeutics. ( Ahmed, A; Hashim, Z; Ilyas, A; Syed, B; Syed, N; Zarina, S, 2023) |
| "Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis." | 5.69 | Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. ( Anders, CK; Arisa, O; Armstrong, TS; Brastianos, P; Burton, E; Carter, S; Connolly, RM; Figg, WD; Gilbert, MR; Houston, N; Jenkins, S; Khan, I; Lipkowitz, S; Mendoza, TR; Mozarsky, B; Nousome, D; Peer, CJ; Shah, R; Smart, DD; Smith, KL; Steeg, PS; Steinberg, SM; Tweed, C; Vera, E; Wu, X; Zhang, W; Zimmer, AS, 2023) |
| "Breast cancer is a hormone-dependent malignancy and is the most prevalent cause of cancer-related mortality among females." | 5.46 | BMI-1 Promotes Self-Renewal of Radio- and Temozolomide (TMZ)-Resistant Breast Cancer Cells. ( Hu, Z; Ma, W; Wang, Y; Yan, Y; Zhang, K; Zhao, P, 2017) |
| "Veliparib and temozolomide demonstrated clinical activity in platinum-naïve BRCA-associated metastatic breast cancer with manageable toxicity at doses of veliparib well below the single-agent active dose." | 5.41 | Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. ( Chabner, BA; Ellisen, LW; Garber, JE; Gelman, RS; Goss, PE; Habin, K; Isakoff, SJ; Keenan, TE; Overmoyer, B; Tung, NM; Winer, EP; Xu, J; Yeap, BY, 2021) |
| "The management of brain metastases (BM) from breast cancer (BC) needs to be improved, and new therapeutic strategies are urgently requested." | 5.38 | Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. ( Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; Iodice, P; Lombardi, A; Montella, L; Parlato, C; Prete, SD; Russo, P; Salzano, A; Sperlongano, P; Sperlongano, R; Vincenzi, B, 2012) |
| " After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m(2) day 1-5/7." | 5.35 | Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. ( Buhk, JH; Hoffmann, AL; Strik, H, 2009) |
| " This phase II study examined the safety and efficacy of intermittent veliparib with carboplatin/paclitaxel (VCP) or temozolomide (VT) in patients with BRCA1/2-mutated breast cancer." | 5.27 | Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. ( Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML, 2018) |
| "Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clinical trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer." | 5.24 | A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. ( Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Giranda, VL; Han, HS; Isakoff, SJ; Johnson, EF; Kaufman, B; Maag, D; Puhalla, S; Qin, Q; Robson, M; Shepherd, SP; Telli, ML, 2017) |
| "To improve the therapeutic index of whole-brain radiation therapy (WBRT) in the treatment of brain metastases (BM) from breast cancer, we investigated the efficacy and safety of WBRT combined with temozolomide (TMZ) in this population." | 5.20 | Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. ( Bourgier, C; Cao, KI; Gerber, S; Gobillion, A; Kirova, YM; Le Scodan, R; Lebas, N; Levy, C; Pierga, JY; Savignoni, A, 2015) |
| "This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma." | 5.14 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010) |
| "A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer." | 5.12 | Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006) |
| "Temozolomide is an oral alkylating agent that crosses the blood-brain barrier, and has preclinical activity in breast cancer." | 5.12 | Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). ( Bordeleau, L; Charpentier, D; Crump, M; Eisenhauer, E; Matthews, S; Trudeau, ME; Yelle, L, 2006) |
| "Triple negative breast cancer cell lines have been reported to be resistant to the cyotoxic effects of temozolomide (TMZ)." | 3.81 | Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells. ( Krishnamurthy, N; Liu, L; Montano, MM; Xiong, X; Zhang, J, 2015) |
| "Temozolomide profoundly prevented the outgrowth of experimental brain metastases of breast cancer in an MGMT-dependent manner." | 3.80 | Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. ( Biernat, W; Duchnowska, R; Gril, B; Hewitt, SM; Hua, E; Jassem, J; Liewehr, DJ; Palmieri, D; Qian, Y; Sosińska-Mielcarek, K; Stark, AM; Steeg, PS; Steinberg, SM; Woditschka, S, 2014) |
| " This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers." | 3.74 | PARP inhibitors and cancer therapy - early results and potential applications. ( Jones, C; Plummer, ER, 2008) |
| "A case is reported in which temozolomide, a promising new DNA alkylating agent, was successfully used to treat radiation refractory metastatic brain tumors arising from primary breast cancer." | 3.71 | Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report. ( Isaacson, BJ; Islam, R; Ratanawong, C; Tipping, SJ; Zickerman, PM, 2002) |
| " The biological effects of two novel PARP inhibitors, NU1025 (8-hydroxy-2-methylquinazolin-4-[3H]one, Ki = 48 nM) and NU1085 [2-(4-hydroxyphenyl)benzamidazole-4-carboxamide, Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer)." | 3.70 | Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. ( Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW, 2000) |
| "Temozolomide was used in the treatment arm in the BROCADE trial." | 3.01 | PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis. ( Abu-Khalaf, M; Kunwor, R; Silver, DP, 2023) |
| "Primary end point is freedom from new brain metastases at 1 year." | 2.94 | Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. ( Armstrong, TS; Biassou, N; Brastianos, PK; Burton, E; Carter, S; Gilbert, MR; Gril, B; Houston, N; Lipkowitz, S; Lyden, D; Smart, DD; Steeg, PS; Steinberg, SM; Zimmer, AS, 2020) |
| "The LMD source was breast cancer (53 %) and non-small-cell lung cancer (37 %)." | 2.77 | Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. ( Balañá, C; Bruna, J; Chacón, I; Gil, M; Langa, JM; Martín, M; Segura, PP, 2012) |
| "33 patients with brain metastases were included in the study and treated with TMZ 60 mg/m2/day (days 1-16) concomitantly with WBI (36 Gy/12 fractions given in 16 days)." | 2.73 | Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. ( Balafouta, MJ; Kolokouris, D; Kouloulias, VE; Kouvaris, JR; Miliadou, A; Papacharalampous, XN; Vlahos, LJ, 2007) |
| " We designed a new regimen utilizing dose-intensified, protracted course of TMZ in combination with vinorelbine, a lipophilic large-spectrum agent, in an attempt to improve the efficacy of TMZ." | 2.72 | Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. ( Abrey, LE; Demopoulos, A; Malkin, MG; Omuro, AM; Raizer, JJ, 2006) |
| "Patients (n=32) with brain metastases were treated with TMZ 150 mg/m2/day (chemotherapy-pretreated) or 200 mg/m2/day (chemotherapy-naive) for 5 days, combined with CDDP 75 mg/m2 on day 1, every 28 days." | 2.71 | Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. ( Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005) |
| "Temozolomide was initially studied intravenously at doses between 50-200 mg m-2 and subsequently was given orally up to 1,200 mg m-2." | 2.67 | Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). ( Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS, 1992) |
| "The standard treatment for brain metastases is radiotherapy." | 2.55 | Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. ( Luo, Y; Tang, J; Tian, J; Xiang, J, 2017) |
| "The incidence of brain metastases from breast cancer is increasing with diagnosis and therapeutics progress, especially with systemic therapies." | 2.50 | [Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer]. ( Cao, KI; Kirova, YM, 2014) |
| "Human breast cancer is among one major health concerns with high prevalence and mortality among women worldwide." | 1.91 | Novel Synergistic Combination of Pamidronate and Temozolomide for Breast Cancer Therapeutics. ( Ahmed, A; Hashim, Z; Ilyas, A; Syed, B; Syed, N; Zarina, S, 2023) |
| "Glioblastoma is the most common primary brain tumor in adults." | 1.51 | ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. ( Al-Omaishi, S; Celebre, A; Chan, J; Das, S; Dirks, PB; Ghannad-Zadeh, K; Guan, J; Isaev, K; Kaskun, O; Moran, MF; Morrissy, AS; Munoz, DG; Reimand, J; Sachdeva, R; Smiljanic, S; Taylor, MD; Tong, J; Wilson, TM; Wu, M, 2019) |
| "Breast cancer is a hormone-dependent malignancy and is the most prevalent cause of cancer-related mortality among females." | 1.46 | BMI-1 Promotes Self-Renewal of Radio- and Temozolomide (TMZ)-Resistant Breast Cancer Cells. ( Hu, Z; Ma, W; Wang, Y; Yan, Y; Zhang, K; Zhao, P, 2017) |
| "Zj6413 treated breast cancers (BCs) showed an elevated level of DNA damage evidenced by the accumulation of γ-H2AX foci and DNA damaged related proteins." | 1.43 | Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. ( Chen, J; Chen, X; Ji, M; Jin, J; Xu, B; Xue, N; Zhou, J; Zhou, Q, 2016) |
| "In a cohort of HER2+ breast cancer brain metastases, we identified a gene expression signature that anti-correlates with overexpression of BRCA1." | 1.40 | A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. ( Akbari, MR; Aldape, KD; Denton-Schneider, BR; Hicks, D; Lee, J; McMullin, RP; Moulis, S; Narod, SA; Ramaswamy, S; Sgroi, DC; Singavarapu, R; Steeg, PS; Wittner, BS; Yang, C, 2014) |
| "The management of brain metastases (BM) from breast cancer (BC) needs to be improved, and new therapeutic strategies are urgently requested." | 1.38 | Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. ( Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; Iodice, P; Lombardi, A; Montella, L; Parlato, C; Prete, SD; Russo, P; Salzano, A; Sperlongano, P; Sperlongano, R; Vincenzi, B, 2012) |
| "Our results of combined treatment of brain metastases are presented and available approaches to brain irradiation and chemotherapy are discussed." | 1.37 | [Brain metastasis in breast cancer]. ( Ivanov, VG; Korytova, LI; Masliukova, EA; Meshechkin, AV; Zhabuna, RM, 2011) |
| "MCF-7 breast cancer cells expressing the α(v)β(3) [alpha(v)beta(3)] integrin receptor are considered as appropriate candidates for such a targeted therapy." | 1.36 | A cyclic-RGD-BioShuttle functionalized with TMZ by DARinv "Click Chemistry" targeted to αvβ3 integrin for therapy. ( Bäuerle, T; Braun, K; Ehemann, V; Fleischhacker, H; Lorenz, P; Müller, G; Pipkorn, R; Waldeck, W; Wiessler, M, 2010) |
| " After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m(2) day 1-5/7." | 1.35 | Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. ( Buhk, JH; Hoffmann, AL; Strik, H, 2009) |
| "First clinical reports on treating brain metastases with temozolomide describe varying effects." | 1.35 | Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. ( Heppner, FL; Ingold, B; Moch, H; Schraml, P, 2009) |
| " 10b is aqueous soluble, orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast xenograph model in combination with cisplatin." | 1.35 | Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. ( Bontcheva-Diaz, V; Bouska, JJ; Donawho, CK; Frost, DJ; Fry, EH; Gandhi, VB; Giranda, VL; Gong, J; Grandel, R; Johnson, EF; Klinghofer, V; Liu, X; Lubisch, W; Luo, Y; Marsh, KC; Olson, AM; Park, CH; Penning, TD; Rosenberg, SH; Shi, Y; Thomas, S; Wernet, W; Zhu, GD, 2008) |
| " PaTrin-2 effectively inactivated MGMT in MCF-7 cells (IC(50) approximately 6 nM) and in xenografts there was complete inactivation of MGMT within 2 h of dosing (20 mg kg(-1) i." | 1.33 | O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. ( Clemons, M; Howell, A; Kelly, J; Margison, GP; McElhinney, RS; McMurry, TB; Watson, AJ, 2005) |
| "Temozolomide was studied using a continuous exposure at final concentrations from 0." | 1.30 | Activity of temozolomide against human tumor colony-forming units. ( Dugan, M; Gerson, SL; Izbicka, E; Raymond, E; Soda, H; Von Hoff, DD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.92) | 18.2507 |
| 2000's | 21 (41.18) | 29.6817 |
| 2010's | 22 (43.14) | 24.3611 |
| 2020's | 6 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Dumont-Hornebeck, B | 1 |
| Strube, YN | 1 |
| Vasilescu, D | 1 |
| Jean-Claude, BJ | 1 |
| Syed, N | 1 |
| Ilyas, A | 1 |
| Syed, B | 1 |
| Ahmed, A | 1 |
| Zarina, S | 1 |
| Hashim, Z | 1 |
| Jenkins, S | 1 |
| Zhang, W | 1 |
| Steinberg, SM | 3 |
| Nousome, D | 1 |
| Houston, N | 2 |
| Wu, X | 2 |
| Armstrong, TS | 2 |
| Burton, E | 2 |
| Smart, DD | 2 |
| Shah, R | 1 |
| Peer, CJ | 1 |
| Mozarsky, B | 1 |
| Arisa, O | 1 |
| Figg, WD | 1 |
| Mendoza, TR | 1 |
| Vera, E | 1 |
| Brastianos, P | 1 |
| Carter, S | 2 |
| Gilbert, MR | 2 |
| Anders, CK | 1 |
| Connolly, RM | 1 |
| Tweed, C | 1 |
| Smith, KL | 1 |
| Khan, I | 1 |
| Lipkowitz, S | 2 |
| Steeg, PS | 4 |
| Zimmer, AS | 2 |
| Kunwor, R | 1 |
| Silver, DP | 1 |
| Abu-Khalaf, M | 1 |
| Biassou, N | 1 |
| Gril, B | 2 |
| Brastianos, PK | 1 |
| Lyden, D | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 4 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Li, X | 10 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 2 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, Y | 3 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 3 |
| Ma, Q | 1 |
| Wang, J | 4 |
| Zhang, E | 1 |
| Zhang, J | 4 |
| Li, Y | 5 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 3 |
| Yan, Z | 2 |
| Wang, Y | 3 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 2 |
| Ren, Y | 1 |
| Li, J | 7 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 2 |
| Wang, W | 1 |
| Wang, S | 2 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 1 |
| Zhu, J | 2 |
| Zhang, L | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Wang, X | 5 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Zhang, Y | 4 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 2 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 1 |
| Zhang, M | 4 |
| Zhang, H | 1 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 2 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 2 |
| Liu, Y | 4 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 3 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 4 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 3 |
| Shi, Y | 2 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Li, C | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Wang, Z | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 2 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 1 |
| He, Z | 1 |
| Chen, B | 1 |
| Wu, J | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 2 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 2 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 2 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Xu, J | 1 |
| Keenan, TE | 1 |
| Overmoyer, B | 1 |
| Tung, NM | 1 |
| Gelman, RS | 1 |
| Habin, K | 1 |
| Garber, JE | 3 |
| Ellisen, LW | 1 |
| Winer, EP | 1 |
| Goss, PE | 1 |
| Yeap, BY | 1 |
| Chabner, BA | 1 |
| Isakoff, SJ | 3 |
| Luo, Y | 2 |
| Xiang, J | 1 |
| Tang, J | 1 |
| Han, HS | 2 |
| Diéras, V | 2 |
| Robson, M | 2 |
| Palácová, M | 1 |
| Marcom, PK | 1 |
| Jager, A | 1 |
| Bondarenko, I | 1 |
| Citrin, D | 1 |
| Campone, M | 1 |
| Telli, ML | 2 |
| Domchek, SM | 2 |
| Friedlander, M | 2 |
| Kaufman, B | 2 |
| Shparyk, Y | 1 |
| Chmielowska, E | 1 |
| Jakobsen, EH | 1 |
| Kaklamani, V | 1 |
| Gradishar, W | 1 |
| Ratajczak, CK | 1 |
| Nickner, C | 1 |
| Qin, Q | 2 |
| Shepherd, SP | 2 |
| Puhalla, S | 2 |
| Tutt, A | 1 |
| Sachdeva, R | 1 |
| Smiljanic, S | 1 |
| Kaskun, O | 1 |
| Ghannad-Zadeh, K | 1 |
| Celebre, A | 1 |
| Isaev, K | 1 |
| Morrissy, AS | 1 |
| Guan, J | 1 |
| Tong, J | 1 |
| Chan, J | 1 |
| Wilson, TM | 1 |
| Al-Omaishi, S | 1 |
| Munoz, DG | 1 |
| Dirks, PB | 1 |
| Moran, MF | 1 |
| Taylor, MD | 1 |
| Reimand, J | 1 |
| de Azambuja, E | 1 |
| Zardavas, D | 1 |
| Lemort, M | 1 |
| Rossari, J | 1 |
| Moulin, C | 1 |
| Buttice, A | 1 |
| D'Hondt, V | 1 |
| Lebrun, F | 1 |
| Lalami, Y | 1 |
| Cardoso, F | 1 |
| Sotiriou, C | 1 |
| Gil, T | 1 |
| Devriendt, D | 1 |
| Paesmans, M | 1 |
| Piccart-Gebhart, M | 1 |
| Awada, A | 1 |
| McMullin, RP | 1 |
| Wittner, BS | 1 |
| Yang, C | 1 |
| Denton-Schneider, BR | 1 |
| Hicks, D | 1 |
| Singavarapu, R | 1 |
| Moulis, S | 1 |
| Lee, J | 1 |
| Akbari, MR | 1 |
| Narod, SA | 1 |
| Aldape, KD | 1 |
| Ramaswamy, S | 1 |
| Sgroi, DC | 1 |
| Palmieri, D | 1 |
| Duchnowska, R | 1 |
| Woditschka, S | 1 |
| Hua, E | 1 |
| Biernat, W | 1 |
| Sosińska-Mielcarek, K | 1 |
| Stark, AM | 1 |
| Hewitt, SM | 1 |
| Liewehr, DJ | 1 |
| Jassem, J | 1 |
| Minniti, G | 1 |
| Scaringi, C | 1 |
| Lanzetta, G | 1 |
| Bozzao, A | 1 |
| Romano, A | 1 |
| De Sanctis, V | 1 |
| Valeriani, M | 1 |
| Osti, M | 1 |
| Enrici, RM | 1 |
| Cao, KI | 2 |
| Kirova, YM | 2 |
| Lebas, N | 1 |
| Gerber, S | 1 |
| Levy, C | 1 |
| Le Scodan, R | 1 |
| Bourgier, C | 1 |
| Pierga, JY | 1 |
| Gobillion, A | 1 |
| Savignoni, A | 1 |
| Krishnamurthy, N | 1 |
| Xiong, X | 1 |
| Montano, MM | 1 |
| Zhou, Q | 1 |
| Ji, M | 1 |
| Zhou, J | 1 |
| Jin, J | 1 |
| Xue, N | 1 |
| Xu, B | 1 |
| Johnson, EF | 2 |
| Maag, D | 1 |
| Giranda, VL | 2 |
| Park, JS | 1 |
| Kim, IK | 1 |
| Han, S | 1 |
| Park, I | 1 |
| Kim, C | 1 |
| Bae, J | 1 |
| Oh, SJ | 1 |
| Lee, S | 1 |
| Kim, JH | 1 |
| Woo, DC | 1 |
| Augustin, HG | 1 |
| Kim, I | 1 |
| Lee, D | 1 |
| Koh, GY | 1 |
| Yan, Y | 1 |
| Zhao, P | 1 |
| Ma, W | 1 |
| Hu, Z | 1 |
| Zhang, K | 1 |
| Penning, TD | 1 |
| Zhu, GD | 1 |
| Gandhi, VB | 1 |
| Gong, J | 1 |
| Thomas, S | 1 |
| Lubisch, W | 1 |
| Grandel, R | 1 |
| Wernet, W | 1 |
| Park, CH | 1 |
| Fry, EH | 1 |
| Klinghofer, V | 1 |
| Donawho, CK | 1 |
| Frost, DJ | 1 |
| Bontcheva-Diaz, V | 1 |
| Bouska, JJ | 1 |
| Olson, AM | 1 |
| Marsh, KC | 1 |
| Rosenberg, SH | 1 |
| Addeo, R | 2 |
| De Rosa, C | 1 |
| Faiola, V | 1 |
| Leo, L | 1 |
| Cennamo, G | 2 |
| Montella, L | 2 |
| Guarrasi, R | 1 |
| Vincenzi, B | 2 |
| Caraglia, M | 2 |
| Del Prete, S | 2 |
| Jones, C | 1 |
| Plummer, ER | 1 |
| Ingold, B | 1 |
| Schraml, P | 1 |
| Heppner, FL | 1 |
| Moch, H | 1 |
| Siena, S | 1 |
| Crinò, L | 1 |
| Danova, M | 1 |
| Cascinu, S | 1 |
| Salvagni, S | 1 |
| Schiavetto, I | 1 |
| Vitali, M | 1 |
| Bajetta, E | 1 |
| Hoffmann, AL | 1 |
| Buhk, JH | 1 |
| Strik, H | 1 |
| Braun, K | 1 |
| Wiessler, M | 1 |
| Pipkorn, R | 1 |
| Ehemann, V | 1 |
| Bäuerle, T | 1 |
| Fleischhacker, H | 1 |
| Müller, G | 1 |
| Lorenz, P | 1 |
| Waldeck, W | 1 |
| Guha, M | 1 |
| Korytova, LI | 1 |
| Meshechkin, AV | 1 |
| Zhabuna, RM | 1 |
| Masliukova, EA | 1 |
| Ivanov, VG | 1 |
| Segura, PP | 1 |
| Gil, M | 1 |
| Balañá, C | 1 |
| Chacón, I | 1 |
| Langa, JM | 1 |
| Martín, M | 1 |
| Bruna, J | 1 |
| Tallet, A | 1 |
| Kirova, Y | 1 |
| Sperlongano, P | 1 |
| Carraturo, M | 1 |
| Iodice, P | 1 |
| Russo, P | 1 |
| Parlato, C | 1 |
| Salzano, A | 1 |
| Lombardi, A | 1 |
| Sperlongano, R | 1 |
| Prete, SD | 1 |
| Islam, R | 1 |
| Isaacson, BJ | 1 |
| Zickerman, PM | 1 |
| Ratanawong, C | 1 |
| Tipping, SJ | 1 |
| Rinne, M | 1 |
| Caldwell, D | 1 |
| Kelley, MR | 1 |
| Christodoulou, C | 1 |
| Bafaloukos, D | 1 |
| Linardou, H | 1 |
| Aravantinos, G | 1 |
| Bamias, A | 1 |
| Carina, M | 1 |
| Klouvas, G | 1 |
| Skarlos, D | 1 |
| Narita, Y | 1 |
| Clemons, M | 1 |
| Kelly, J | 1 |
| Watson, AJ | 1 |
| Howell, A | 1 |
| McElhinney, RS | 1 |
| McMurry, TB | 1 |
| Margison, GP | 1 |
| Kato, Y | 1 |
| Okollie, B | 1 |
| Artemov, D | 1 |
| Trudeau, ME | 1 |
| Crump, M | 1 |
| Charpentier, D | 1 |
| Yelle, L | 1 |
| Bordeleau, L | 1 |
| Matthews, S | 1 |
| Eisenhauer, E | 1 |
| Omuro, AM | 1 |
| Raizer, JJ | 1 |
| Demopoulos, A | 1 |
| Malkin, MG | 1 |
| Abrey, LE | 1 |
| Noronha, V | 1 |
| Berliner, N | 1 |
| Ballen, KK | 1 |
| Lacy, J | 1 |
| Kracher, J | 1 |
| Baehring, J | 1 |
| Henson, JW | 1 |
| Rivera, E | 1 |
| Meyers, C | 1 |
| Groves, M | 1 |
| Valero, V | 1 |
| Francis, D | 1 |
| Arun, B | 1 |
| Broglio, K | 1 |
| Yin, G | 1 |
| Hortobagyi, GN | 1 |
| Buchholz, T | 1 |
| Weller, M | 1 |
| Kouvaris, JR | 1 |
| Miliadou, A | 1 |
| Kouloulias, VE | 1 |
| Kolokouris, D | 1 |
| Balafouta, MJ | 1 |
| Papacharalampous, XN | 1 |
| Vlahos, LJ | 1 |
| Sawrie, SM | 1 |
| Guthrie, BL | 1 |
| Spencer, SA | 1 |
| Nordal, RA | 1 |
| Meredith, RF | 1 |
| Markert, JM | 1 |
| Cloud, GA | 1 |
| Fiveash, JB | 1 |
| Caporali, S | 1 |
| Levati, L | 1 |
| Starace, G | 1 |
| Ragone, G | 1 |
| Bonmassar, E | 1 |
| Alvino, E | 1 |
| D'Atri, S | 1 |
| Raymond, E | 1 |
| Izbicka, E | 1 |
| Soda, H | 1 |
| Gerson, SL | 1 |
| Dugan, M | 1 |
| Von Hoff, DD | 1 |
| Delaney, CA | 1 |
| Wang, LZ | 1 |
| Kyle, S | 1 |
| White, AW | 1 |
| Calvert, AH | 1 |
| Curtin, NJ | 1 |
| Durkacz, BW | 1 |
| Hostomsky, Z | 1 |
| Newell, DR | 1 |
| Newlands, ES | 1 |
| Blackledge, GR | 1 |
| Slack, JA | 1 |
| Rustin, GJ | 1 |
| Smith, DB | 1 |
| Stuart, NS | 1 |
| Quarterman, CP | 1 |
| Hoffman, R | 1 |
| Stevens, MF | 1 |
| Brampton, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery[NCT03190967] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2018-04-18 | Terminated (stopped due to The phase II portion was never started as we could no longer get the drug from the manufacturer.) | ||
| A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers[NCT01009788] | Phase 2 | 64 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | ||
| Nitroglycerin Plus Whole Intracranial Radiotherapy for Brain Metastases in Non-small Cell Lung Cancer Patients: a Phase II Open Randomized Clinical Trial[NCT04338867] | Phase 2 | 96 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
| A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation [NCT01506609] | Phase 2 | 294 participants (Actual) | Interventional | 2012-01-23 | Completed | ||
| Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer[NCT00875355] | Phase 2 | 100 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-small Cell Lung Cancer.[NCT00831545] | Phase 2 | 162 participants (Actual) | Interventional | 2000-12-01 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Maximum tolerated dose of TMZ when used in combination with T-DM1. MTD is defined as the dose level at which 0 or 1 participant in 6 has a dose limiting toxicity (DLT). A DLT is defined as grade 3 or higher non-hematologic adverse events excluding grade 3 hypertension controlled with anti-hypertensive therapy; or grade 3 asymptomatic electrolytes imbalance; grade 3 endocrinopathy; grade 3 asymptomatic increase in aspartate aminotransferase or alanine aminotransferase; and transient (lasting less than <48 hours) nausea, emesis, or diarrhea if corrected with conservative measures within 24-48 hours. A hematologic grade 4 neutropenia of ≥ 7 days duration, grade ≥ 3 thrombocytopenia, and all other grade 4 hematologic toxicities excluding grade 4 lymphopenia, or leukopenia in the absence of grade 3 or higher neutropenia. Grade 3 is severe. Grade 4 is life-threatening. (NCT03190967)
Timeframe: first 21 days of treatment
| Intervention | mg/m^2 (Number) |
|---|---|
| All Participants | 40 |
Median amount of time participants survives after therapy. Survival compared between the two arms and Kaplan-Meier curves constructed with a two-tailed log-rank test used to compare the arms. (NCT03190967)
Timeframe: From date of first therapy until death, an average of 40.79 months
| Intervention | Months (Median) |
|---|---|
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 37.8 |
| Level 2 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 48.4 |
| Level 3 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 38.5 |
Number of participants with DLTs at each dose level 30 days after treatment. A DLT is defined as grade 3 or higher non-hematologic adverse events excluding grade 3 hypertension controlled with anti-hypertensive therapy; or grade 3 asymptomatic electrolytes imbalance; grade 3 endocrinopathy; grade 3 asymptomatic increase in aspartate aminotransferase or alanine aminotransferase; and transient (lasting less than <48 hours) nausea, emesis, or diarrhea if corrected with conservative measures within 24-48 hours. A hematologic grade 4 neutropenia of ≥ 7 days duration, grade ≥ 3 thrombocytopenia, and all other grade 4 hematologic toxicities excluding grade 4 lymphopenia, or leukopenia in the absence of grade 3 or higher neutropenia. Grade 3 is severe. Grade 4 is life-threatening. (NCT03190967)
Timeframe: After first cycle of treatment, up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 0 |
| Level 2 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 0 |
| Level 3 Phase I:Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 0 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT03190967)
Timeframe: Date treatment consent signed to date off study, approximately 44 months and 27 days for level 1, 28 months and 10 days for level 2, and 40 months and 8 days for level 3.
| Intervention | Participants (Count of Participants) |
|---|---|
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 3 |
| Level 2 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 3 |
| Level 3 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 6 |
TTP is the time between the first day of treatment to the day of disease progression. Progression was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 25% increase in the sum of products of all measurable lesions over smallest sum observed, clear worsening of any evaluable disease, appearance of any new lesion/site, or failure to return for evaluation due to death or deteriorating condition. (NCT03190967)
Timeframe: From first day of treatment to the day of disease progression, an average of 15 months.
| Intervention | Months (Mean) |
|---|---|
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 6.95 |
| Level 2 Phase I:Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 16.26 |
| Level 3 Phase I:Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 17.46 |
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 3 is severe. Grade 4 is life-threatening. (NCT03190967)
Timeframe: Evaluated at the beginning of every cycle while on study, for an average of 9.6 months (range 2.8-33.9 months).
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 Anemia | Grade 3 Aspartate aminotransferase increased | Grade 3 CD4 lymphocytes decreased | Grade 3 Dysphasia | Grade 3 Hypokalemia | Grade 3 Lymphocyte count decreased | Grade 3 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Malignant Neoplasm-CML | Grade 3 Neutrophil count decreased | Grade 3 Platelet count decreased | Grade 3 Surgical and medical procedures - Other, Lap Cholecystectomy/Hernia Repair | Grade 3 White blood cell decreased | Grade 4 White blood cell decreased | Grade 4 CD4 lymphocytes decreased | Grade 4 Lymphocyte count decreased | Grade 5 | |
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Level 2 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Level 3 Phase I:Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 0 | 1 | 5 | 0 | 1 | 5 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 0 |
EORTC QLQ-CIPN20 sensory subscale score was calculated following the standard scoring algorithm, transformed to a 0 (low quality of life) to 100 (best quality of life) scale. A positive change from baseline indicates improvement. (NCT01506609)
Timeframe: Baseline, Week 18
| Intervention | score on a scale (Mean) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 13.94 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 11.24 |
"CBR: percentage of participants who were progression-free at 18 weeks, defined as complete response (CR), partial response (PR), stable disease (SD) or non-CR/non-disease progression (PD) per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1.~CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 0 mm. PR: >= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters (SOD). PD: >= 20% increase in the SOD of target lesions, taking as reference the smallest SOD recorded since the treatment started (baseline or after) or the appearance of >=1 new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after)." (NCT01506609)
Timeframe: Week 18
| Intervention | percentage of participants (Number) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 87.0 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 90.7 |
| Group 2 Veliparib + TMZ | 73.0 |
The objective response rate, defined as percentage of participants with a confirmed CR or PR based on RECIST 1.1 criteria. CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 0 mm. PR: >= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline SODs. (NCT01506609)
Timeframe: Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for ORR was 34 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 61.3 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 77.8 |
| Group 2 Veliparib + TMZ | 28.6 |
Time to death for a given participant was defined as the number of months from the day the participant is randomized to the date of the participant's death. All events of death were included, regardless of whether the event occurs while the participant was still taking study drug, or after the participant discontinued study drug. If a participant had not died, then the data will be censored at the date when the participant was last known to be alive. (NCT01506609)
Timeframe: From Cycle 1 Day 1 until participant's death or 3 years post discontinuation (data cutoff date: 04 March 2016); maximum duration of follow up for OS was 72 months.
| Intervention | months (Median) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 25.4 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 28.3 |
| Group 2 Veliparib + TMZ | 19.1 |
PFS is defined as the number of months from the date the participant was randomized to the date of radiographic progression as determined by the central imaging center, or to the date of all cause deaths within 63 days of last tumor assessment if disease progression was not reached. (NCT01506609)
Timeframe: Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for PFS was 34 months.
| Intervention | months (Median) |
|---|---|
| Group 2 Placebo + Carboplatin/Paclitaxel | 12.3 |
| Group 2 Veliparib + Carboplatin/Paclitaxel | 14.1 |
| Group 2 Veliparib + TMZ | 7.4 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
7 reviews available for temozolomide and Breast Neoplasms
| Article | Year |
|---|---|
PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Humans; Poly(ADP-ribose) Polymerase Inhibito | 2023 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2017 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barri | 2014 |
[Brain metastases from breast cancer: prognostic factors and tailored management].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Daca | 2013 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasm | 2005 |
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.
Topics: Aged; Breast Neoplasms; Dacarbazine; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndr | 2006 |
18 trials available for temozolomide and Breast Neoplasms
| Article | Year |
|---|---|
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Topics: Ado-Trastuzumab Emtansine; Brain Neoplasms; Breast Neoplasms; Cell-Free Nucleic Acids; Female; Human | 2023 |
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; Breast Neoplasms; Car | 2021 |
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Breas | 2018 |
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Daca | 2013 |
Whole brain reirradiation and concurrent temozolomide in patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcin | 2014 |
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Combined Modality | 2015 |
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Breast | 2017 |
Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Carcinoma, | 2008 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2010 |
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Da | 2012 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea | 2005 |
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; | 2006 |
Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2006 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carci | 2007 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
27 other studies available for temozolomide and Breast Neoplasms
| Article | Year |
|---|---|
Design and synthesis of a novel water soluble benzotetrazepinone.
Topics: Antineoplastic Agents, Alkylating; Azepines; Breast Neoplasms; Cell Survival; Drug Design; Female; H | 2000 |
Novel Synergistic Combination of Pamidronate and Temozolomide for Breast Cancer Therapeutics.
Topics: Autoantigens; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Pamidronate; Proteomics; Temozolom | 2023 |
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.
Topics: Benzimidazoles; Breast Neoplasms; Carboplatin; Humans; Neoplasm Recurrence, Local; Paclitaxel; Temoz | 2018 |
ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; BRCA1 Protein; B | 2014 |
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Dac | 2014 |
Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells.
Topics: Alkylating Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Breaks, Doubl | 2015 |
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2016 |
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.
Topics: Animals; Antibodies; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Dacarbazine; Dr | 2016 |
BMI-1 Promotes Self-Renewal of Radio- and Temozolomide (TMZ)-Resistant Breast Cancer Cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cisplatin | 2008 |
PARP inhibitors and cancer therapy - early results and potential applications.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; En | 2008 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification | 2009 |
Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined M | 2009 |
A cyclic-RGD-BioShuttle functionalized with TMZ by DARinv "Click Chemistry" targeted to αvβ3 integrin for therapy.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tumor; Cell Size; Dacarbazine; Femal | 2010 |
PARP inhibitors stumble in breast cancer.
Topics: Alleles; Antineoplastic Agents, Alkylating; Breast Neoplasms; Clinical Trials as Topic; Dacarbazine; | 2011 |
[Brain metastasis in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cystitis; Dacarbazine; Female; | 2002 |
Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells.
Topics: Adenoviridae; Alkylating Agents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Br | 2004 |
O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
Topics: Animals; Body Weight; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resi | 2005 |
Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carbon Isotopes; Contr | 2006 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2007 |
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms | 2008 |
AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; B-Lymphocytes; Breast Neo | 2008 |
Activity of temozolomide against human tumor colony-forming units.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 1997 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazin | 2000 |